Tag: NASDAQ: PIRS

Business

Pieris Pharmaceutical Inc. (NASDAQ: PIRS) Jumps 23% after FDA Grants Its HER2 Cancer Treatment Orphan Drug Designation

Pieris Pharmaceutical Inc. (NASDAQ: PIRS) jumped 23.45%  has announced that the FDA has granted its cinrebafusp alfa (PRS-343)  orphan drug designation for HER2-low and HER2-high expressing gastric cancers treatment.  Cinrebafusp receives orphan drug designation for HER-2 gastric cancer treatment   The FDA gives the orphan drug approval to encourage the development […]